Study guide

Retinal vein and artery occlusions

European Board of Ophthalmology Diploma EBOD

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: EBOD Examination, Applications and Regulations

EBOD Format, Scoring and Revision Planning Eligibility, Applications and the Diploma Online Rules, Technical Preparation and Appeals

2 Chapter 2: Physical Optics, Photometry and Lenses

Light, refraction and total internal reflection Photometry, contrast, colour and adaptation Prisms, decentration and vector combination Vergence, astigmatic lenses and Sturm’s conoid

3 Chapter 3: Instrument Optics, Aberrations and Laser Physics

Cross-cylinder and diagnostic instrument optics Aberrations, duochrome and wavefront analysis Diffraction, polarization, lasers and OCT

4 Chapter 4: Refraction, Accommodation and Spectacle Prescribing

Objective and cycloplegic refraction Subjective refraction and binocular balance Accommodation, presbyopia and vertex distance Spectacle Materials, Measurement and Progressive Lenses

5 Chapter 5: Contact Lenses and Low-Vision Rehabilitation

Contact-lens optics, materials and tear lenses Contact-lens fit and complications Low-vision assessment and magnification Low-vision aids, calculations and ergonomics

6 Chapter 6: Extraocular Anatomy and Motor Physiology

Extraocular muscle anatomy and innervation Eye axes, kinematics and muscle actions Motor laws and orbital pulleys

7 Chapter 7: Binocular Vision and Amblyopia

Binocular vision, stereopsis and the horopter Suppression, correspondence and microtropia Sensory tests and amblyopia treatment

8 Chapter 8: Childhood Assessment and Strabismus Testing

Visual Development, Childhood Testing and Developmental Delay History, corneal reflexes and cover tests Motility patterns, three-step testing and Hess charts

9 Chapter 9: Esotropia, Exotropia and Vertical Deviations

Infantile and accommodative esotropia Exotropia classification and management Vertical Deviations, A–V Patterns and Skew

10 Chapter 10: Dysinnervation, Nystagmus and Muscle Surgery

Duane syndrome, Brown syndrome and restriction Nystagmus patterns and investigation Nystagmus and muscle surgery principles

11 Chapter 11: ROP and Paediatric Ocular Disease

Retinopathy of Prematurity: Screening, Classification and Follow-up Childhood Cataract, Leukocoria and Congenital Glaucoma Childhood Systemic Disease, Infection and Safeguarding

12 Chapter 12: Ocular Surface Anatomy and Infection

Corneal, Conjunctival and Scleral Structure: Examination and Sampling Bacterial keratitis, sampling and treatment Fungal, amoebic and herpetic keratitis Infectious, chlamydial and neonatal conjunctivitis

13 Chapter 13: Allergy, Cicatrisation and Surface Inflammation

Allergic eye disease, trachoma and phlyctenules Cicatrising Conjunctivitis: Mucous Membrane Pemphigoid and SJS/TEN Dry eye, blepharitis and meibomian dysfunction PUK, interstitial keratitis and scleritis

14 Chapter 14: Anterior Segment Dysgenesis and Corneal Dystrophies

Anterior Segment Dysgenesis, Aniridia and Congenital Corneal Opacity IC3D and epithelial or Bowman-layer dystrophies Stromal corneal dystrophies Endothelial corneal dystrophies

15 Chapter 15: Corneal Degeneration, Ectasia and Epithelial Failure

Corneal Degenerations, Pterygium, Band Keratopathy and Dellen Keratoconus and clinical ectasia signs Ectasia imaging, cross-linking and rehabilitation Recurrent Erosion, Neurotrophic Keratopathy and Vitamin A Deficiency

16 Chapter 16: Surface Reconstruction and Keratoplasty

Limbal Stem-Cell Failure, Tarsorrhaphy and Phototherapeutic Keratectomy PK, DALK and endothelial keratoplasty Corneal graft immunity and rejection recognition Graft rejection treatment and postoperative problems

17 Chapter 17: Lens Development, Cataract Assessment and Biometry

Lens Development, Congenital Shape and Ectopia Lentis Lens anatomy and age-related cataract phenotypes Cataract grading, secondary causes and childhood disease Optical and ultrasound biometry

18 Chapter 18: IOL Planning and Phacoemulsification

Keratometry and IOL power formulae Post-refractive biometry, toric alignment and IOL design Phaco fluidics and ultrasound delivery Wounds, OVDs and nucleus techniques

19 Chapter 19: Cataract Anaesthesia and Surgical Complications

Cataract Anaesthesia, Alternative Extraction and Combined Procedures IFIS, capsule rupture and compromised support Postoperative inflammation, haemorrhage and PCO

20 Chapter 20: Corneal and Intraocular Refractive Surgery

Excimer ablation, PRK and LASIK SMILE, surgical selection and complications Phakic IOLs and refractive lens exchange

21 Chapter 21: Presbyopia Procedures and Surface Therapeutics

Presbyopia Surgery, Monovision and Historical Refractive Procedures Surface antimicrobial and anti-inflammatory pharmacology Surface healing, amnion and cenegermin

22 Chapter 22: Aqueous Dynamics, Tonometry and Gonioscopy

Ciliary body and aqueous secretion Outflow and the Goldmann pressure model Tonometry, corneal thickness and biomechanics Gonioscopy optics, landmarks and indentation

23 Chapter 23: Angle, Disc and Visual-Field Assessment

Angle grading and anterior-segment imaging Optic-disc examination and documentation OCT and automated perimetry

24 Chapter 24: Glaucoma Progression, Suspects and Secondary Mechanisms

Field reliability and progression Ocular hypertension, suspects and juvenile glaucoma Lens-related glaucoma, aqueous misdirection and venous pressure

25 Chapter 25: POAG, Angle Closure and Pigmentary Disease

POAG, target pressure and normal-tension disease Angle-closure classification and mechanisms Acute angle closure, iridotomy and lens extraction Pseudoexfoliation and pigmentary glaucoma

26 Chapter 26: Glaucoma Medical, Laser and Surgical Treatment

Neovascular, uveitic and steroid-response glaucoma Glaucoma medicines, SLT and MIGS Trabeculectomy and drainage implants Nonpenetrating surgery, cyclodestruction and postoperative lasers

27 Chapter 27: Retinal Imaging, Diabetes and Vascular Occlusion

Retinal anatomy, examination and multimodal imaging Diabetic microangiopathy and NPDR classification PDR, macular oedema and diabetic trials Retinal vein and artery occlusions

28 Chapter 28: Uncommon Vascular Disease and Myopic Maculopathy

Macroaneurysm, sickle retinopathy and retinal periphlebitis Coats disease and leukocoria assessment MacTel and radiation retinopathy Myopic maculopathy and presumed ocular histoplasmosis

29 Chapter 29: Inherited Retina and Electrophysiology

Retinitis pigmentosa and inherited degeneration Stargardt, Best disease and retinal electrophysiology Cone disorders, stationary night blindness and syndromic retina

30 Chapter 30: AMD, Geographic Atrophy and Pachychoroid

AMD biology and clinical staging Drusen, geographic atrophy and neovascular phenotypes Neovascular AMD trials and treatment CSCR and the pachychoroid spectrum

31 Chapter 31: Retinal Breaks and Detachment Repair

PVD, peripheral degenerations and retinal breaks RRD localization and retinoschisis Detachment mechanisms, pneumatic retinopexy and scleral buckling

32 Chapter 32: Vitrectomy, Macular Surgery and Retinal Trauma

Vitrectomy and intraocular tamponades ERM, macular holes and PVR Retinal trauma, optic-disc pits and choroidal detachment

33 Chapter 33: Uveitis Classification and Non-Infectious Inflammation

SUN classification, grading and uveitis work-up Anterior and intermediate uveitis patterns HLA-B27, sarcoidosis, Behçet disease and VKH Posterior inflammatory patterns and immunomodulation

34 Chapter 34: Infectious Uveitis and Endophthalmitis

Toxoplasmosis and herpetic necrotizing retinitis Ocular syphilis and tuberculosis Immunosuppressed retinitis, toxocariasis and neuroretinitis Endophthalmitis diagnosis and treatment

35 Chapter 35: Optic Neuritis and Ischaemic Optic Neuropathy

Typical optic neuritis and ONTT NMOSD and MOGAD Arteritic optic neuropathy and GCA NAION and ischaemic neuropathy comparison

36 Chapter 36: Papilloedema, IIH and Afferent Localisation

Papilloedema recognition and Frisén grading IIH diagnosis and vision protection Disc drusen and pseudopapilloedema Afferent pathways and chiasmal localization

37 Chapter 37: Congenital, Inherited and Cortical Neuro-Ophthalmology

Cortical vision and higher visual syndromes Neuro-ophthalmic testing and congenital optic discs Inherited, compressive, infiltrative and nutritional optic neuropathies Transient visual loss, headache and neurological emergencies

38 Chapter 38: Central Motor Control and Cranial Nerve Palsies

Central ocular motor control and supranuclear disorders Third- and fourth-nerve palsies Sixth nerve, pontine gaze and cavernous sinus

39 Chapter 39: Myasthenia and Ocular Myopathy

Myasthenic ocular weakness Myasthenia testing and treatment Myopathy, CPEO and Kearns–Sayre syndrome

40 Chapter 40: Pupillary Pathways and Anisocoria

Pupillary pathways and afferent defects Horner syndrome and tonic pupil Light–near dissociation and pupil differentials

41 Chapter 41: Orbit, Thyroid Eye Disease and Ptosis Assessment

Orbital anatomy and thyroid eye disease Orbital infection and idiopathic inflammation Orbital masses, approaches and eye-removal procedures Lid anatomy and ptosis evaluation

42 Chapter 42: Lid Repair and Lacrimal Drainage

Ptosis repair, malposition and eyelid tumours Lash disorders, facial palsy and lid reconstruction Lacrimal drainage and epiphora testing Nasolacrimal obstruction, infection and DCR

43 Chapter 43: Lacrimal Gland Disease, Pathology and Intraocular Tumours

Lacrimal gland inflammation and tumours Ocular histology, specimen handling and special stains Immunophenotyping, molecular pathology and tumour genetics Uveal melanoma and retinoblastoma

44 Chapter 44: Lymphoma, Surface Tumours and Paraneoplastic Disease

Vitreoretinal lymphoma Surface tumours, uveal metastases and benign mimics Paraneoplastic retinopathy, treatment effects and counselling

45 Chapter 45: Ocular Trauma and Vascular Systemic Disease

Trauma terminology and prognostic scoring Chemical injury and surface preservation Open-globe emergency management Vascular, endocrine, pregnancy and renal eye disease

46 Chapter 46: Multisystem Disease and Ophthalmic Pharmacology

Immune, metabolic and multisystem ocular clues Phakomatoses and syndrome-specific surveillance Connective-tissue and metabolic ocular disease Drug delivery and systemic glaucoma effects

47 Chapter 47: Medication Toxicity, Professional Practice and Clinical Stations

Retinal and optic medication toxicity Prevention, consent and professional practice Directed clinical answers and station rehearsal

Retinal vein and artery occlusions

Key Takeaways Explain This Topic AI

RVO management addresses macular oedema, ischaemia, new vessels and systemic vascular risk.

Nonperfusion thresholds depend on imaging field; conventional disc-area criteria are not universal widefield thresholds.

Acute retinal arterial occlusion needs emergency stroke assessment, while current trials do not establish routine thrombolysis as proven visual treatment.

Last updated: October 2026

Central Retinal Vein Occlusion (CRVO)

Central retinal vein occlusion is the second most prevalent vision-threatening retinal vascular pathology worldwide, trailing only diabetic retinopathy. CRVO characteristically impacts older adults in their sixth to eighth decades, driven by systemic cardiovascular risk factors and localized anatomical vulnerabilities.

Pathogenesis: Virchow's Triad at the Lamina Cribrosa

The pathogenesis of CRVO is governed by the principles of Virchow's Triad (haemodynamic stasis, endothelial injury, and hypercoagulability) acting at a unique anatomical bottleneck:

Anatomical Confinement: The central retinal artery and central retinal vein pass together through a narrow, rigid aperture within the fibrous ring of the lamina cribrosa of the sclera, where they share a common adventitial connective tissue sheath.

Mechanical Compression & Stasis: In individuals with systemic hypertension or arteriosclerosis, atheromatous thickening and sclerosis of the relatively thick-walled central retinal artery compresses the thin-walled, compliant central retinal vein against the unyielding scleral rim of the lamina cribrosa. This compression causes luminal stenosis, creating turbulent blood flow, localized haemodynamic stasis, and secondary endothelial shear damage.

Thrombus Formation: Endothelial denudation exposes subendothelial collagen, triggering platelet aggregation, tissue factor release, and secondary intraluminal thrombus formation, totally or sub-totally occluding venous outflow.

Non-Ischaemic vs. Ischaemic CRVO

CRVO manifests as a clinical spectrum divided into two distinct functional and prognostic entities:

  • Clinical & Diagnostic Parameter Non-Ischaemic CRVO (Perfused) Ischaemic CRVO (Non-Perfused)
  • Frequency More common presentation Less common, but identification is essential because of neovascular risk

Presenting Visual Acuity Variable; typically better than 6 / 60 6/60 6/60 ( 20 / 200 20/200 20/200 ) Catastrophic; profound reduction, typically < 6 / 60 <6/60 < 6/60 (CF or HM)

Afferent pupillary defect Often absent or less marked A substantial RAPD supports severe asymmetric retinal ischaemia; account for fellow-eye disease

Funduscopic Appearance Mild disc oedema, scattered flame and blot haemorrhages in 4 quadrants, moderate venous engorgement Severe disc swelling, profound venous tortuosity and engorgement, confluent haemorrhages across all 4 quadrants ( "blood and thunder" fundus ), extensive cotton-wool spots

Fluorescein Angiography < 10 <10 < 10 disc areas of capillary non-perfusion ≥ 10 \ge 10 ≥ 10 disc areas of capillary non-perfusion on conventional seven-field FA; widefield thresholds require separate interpretation

Visual Field Testing Mild peripheral constriction or relative central scotoma Dense absolute scotomas; severe peripheral constriction

Neovascular complications Lower risk; reassess if perfusion worsens Greater risk of iris/angle neovascularisation and neovascular glaucoma

Evolution Can become ischaemic, so follow-up still matters Prognosis and complications depend on ischaemia, oedema and treatment

Warning

The "100-Day Glaucoma" Phenomenon: In ischaemic CRVO, widespread retinal non-perfusion triggers massive intraocular VEGF synthesis. Diffusing into the anterior chamber, VEGF stimulates neovascularisation of the iris (NVI / rubeosis iridis) and neovascularisation of the iridocorneal angle (NVA). Myofibroblastic contraction of fibrovascular membranes unzips the angle, causing peripheral anterior synechiae (PAS), intractable secondary angle closure, and disastrous intraocular pressure elevations: Neovascular Glaucoma (NVG) . The historical term "100-day glaucoma" highlights early risk, not a deadline. Neovascularisation can occur outside that interval, and anti-VEGF treatment may delay its appearance without eliminating ischaemic drive.

Systemic Evaluation in CRVO

Review blood pressure, glucose, lipid and cardiovascular risk, smoking, medications and glaucoma. History and examination may suggest a hyperviscosity, inflammatory or haematological disorder requiring targeted assessment. A young age or bilateral disease can justify further investigation, but routine inherited-thrombophilia or MTHFR panels are not indicated for every young patient. Tests should change management and be coordinated with the appropriate physician. Anticoagulation is not routine treatment for the ocular oedema of RVO.

  • Evidence-Based Management of CRVO
  • 1. Intravitreal Anti-VEGF Pharmacotherapy

Intravitreal anti-VEGF represents the first-line standard of care for macular oedema secondary to CRVO:

CRUISE Trial (Ranibizumab): Evaluated monthly ranibizumab (0.3 mg and 0.5 mg) vs. sham injection. At 6 months, patients receiving ranibizumab 0.5 mg gained a mean of +14.9 letters (compared to +0.8 letters with sham), with 47.7% gaining ≥ 15 \ge 15 ≥ 15 letters.

COPERNICUS and GALILEO Trials (Aflibercept): Evaluated monthly intravitreal aflibercept 2.0 mg vs. sham. At 24 weeks, aflibercept-treated eyes achieved extraordinary visual improvements of +17.3 to +18.0 letters , with over 56% to 60% gaining ≥ 15 \ge 15 ≥ 15 letters .

2. Intravitreal Corticosteroids

GENEVA Trial (Dexamethasone 0.7 mg Implant): Demonstrated that a single biodegradable dexamethasone implant (Ozurdex) produced rapid, statistically significant visual gains ( ≥ 15 \ge 15 ≥ 15 letters in ~30% of eyes at day 60). It serves as an outstanding second-line agent or primary choice in pseudophakic patients, vitrectomised eyes, or individuals unable to maintain monthly anti-VEGF injection schedules.

3. The Role of Panretinal Photocoagulation (CVOS Findings)

The landmark Central Vein Occlusion Study (CVOS) tested whether prophylactic panretinal photocoagulation (PRP) in ischaemic CRVO could prevent neovascular glaucoma:

Important

The CVOS Paradox and Modern Protocol: CVOS supported close surveillance and prompt PRP when iris/angle neovascularisation develops, rather than routine prophylactic PRP in every ischaemic CRVO. Monitor frequently during the high-risk early period and after anti-VEGF cessation. Preventive PRP may be considered when dependable surveillance is impossible, with individual discussion of harms and benefits.

Branch Retinal Vein Occlusion (BRVO)

Branch retinal vein occlusion is approximately three times more common than CRVO, typically presenting with acute, painless, sectoral visual field loss or blur.

Anatomical Predilection and Arteriovenous Crossings

BRVO often arises at an arteriovenous crossing where the artery lies anterior to the vein and shared adventitial tissue can contribute to venous compression. This disease-associated arrangement does not mean arteries are anterior at more than 99% of all normal crossings.

Mechanical Constriction: Arteriolosclerosis and chronic hypertensive thickening of the rigid arteriolar wall compress the underlying, thin-walled compliant venule against the deep retinal tissue.

Superotemporal predilection: BRVO commonly involves the superotemporal arcade, reflecting the distribution of vulnerable arteriovenous crossings; location alone does not establish perfusion or visual prognosis.

Fundus Appearance: A sharply demarcated, wedge-shaped or fan-shaped distribution of flame and blot intraretinal haemorrhages, retinal oedema, and cotton-wool spots extending outward from the offending A/V crossing point, with its apex pointing toward the blockage.

Complications and Landmark Trials in BRVO

Macular oedema: A major cause of sustained central loss. BRAVO compared ranibizumab with sham, whereas VIBRANT compared aflibercept with grid laser. Anti-VEGF is commonly a first-line option; choice incorporates anatomy, lens, pressure, contraindications and visit burden rather than a claim that both trials used a laser comparator.

Retinal neovascularisation: Ischaemic retina increases risk. Look for retinal/disc new vessels and vitreous haemorrhage; nonperfusion alone does not automatically require sector laser.

BVOS Trial (Branch Vein Occlusion Study): Demonstrated that sectoral scatter argon laser photocoagulation applied to the non-perfused retinal quadrant halved the risk of vitreous haemorrhage (reducing haemorrhage rates from 60% down to 30%) in eyes that developed retinal neovascularisation.

Central Retinal Artery Occlusion (CRAO)

CRAO causes sudden usually painless monocular loss from inner-retinal ischaemia. A relative afferent defect, retinal whitening, segmented vessels and a cherry-red fovea support the diagnosis, but may be absent early or vary with incomplete occlusion and cilioretinal supply. The thin foveola lacks the thick inner layers that whiten elsewhere, allowing the underlying choroidal colour to remain visible. A cherry-red spot is not exclusive to CRAO.

Treat suspected acute retinal arterial occlusion as a stroke emergency. Establish symptom onset/last-known-well, activate the local emergency stroke pathway and assess vascular risk and neurological symptoms. In older patients consider giant-cell arteritis: obtain urgent inflammatory markers and treat immediately when clinically suspected, without delaying for confirmation. BRAO can preserve central acuity yet still require stroke assessment. Ocular ischaemic syndrome suggests severe carotid disease and can cause mid-peripheral haemorrhages, anterior ischaemia and delayed choroidal filling; it needs vascular evaluation as well as ocular care.

Ocular massage, anterior-chamber paracentesis and other traditional pressure manipulations have no established visual benefit and can cause harm. Animal ischaemia times are not a precise human deadline for irreversible loss.

Earlier statements about thrombolysis require the current trials. THEIA (2025) did not demonstrate a significant primary visual benefit of alteplase versus aspirin in its limited sample. TenCRAOS (2026) found no significantly better recovery with tenecteplase within 4.5 hours and reported serious safety concerns, including fatal intracranial haemorrhage. This does not support routine thrombolysis as proven ophthalmic treatment. Urgent assessment remains necessary for stroke diagnosis, prevention and any locally approved trial pathway. See THEIA and TenCRAOS .

After the acute event, address cardiovascular secondary prevention through the stroke team, monitor ocular neovascularisation in high-risk eyes and provide visual rehabilitation. Explain prognosis without promising recovery from a particular rescue manoeuvre.

Laser and Imaging Decisions

For BRVO, sector laser treats retinal or disc neovascularisation rather than nonperfusion exceeding five disc areas alone. For CRVO, conventional seven-field and ultra-widefield nonperfusion measures are not interchangeable. Monitor iris and angle before dilation when appropriate and remain vigilant after stopping anti-VEGF. Apply PRP for new vessels, with preventive treatment considered individually when reliable follow-up is impossible. Anti-VEGF primarily treats macular oedema and can suppress or delay visible new vessels without eliminating ischaemia.